SYRE

$0.00

(

+0.00%

)
Quote details

stock

Spyre Therapeutics Inc.

NASDAQ | SYRE

17.00

USD

+$0.00

(

+0.00%

)

At Close (As of Sep 5, 2025)

$1.03B

Market Cap

-

P/E Ratio

-2.53

EPS

$40.26

52 Week High

$10.91

52 Week Low

HEALTHCARE

Sector

SYRE Chart

Recent Chart
Price Action

SYRE Technicals

Tags:

SYRE Earnings

Yearly Income Statement (As of Dec 31, 2024)

Field Value (USD)
Gross Profit $886K
Total Revenue $886K
Cost Of Revenue $964K
Costof Goods And Services Sold $964K
Operating Income -$209M
Selling General And Administrative $46M
Research And Development $163M
Operating Expenses $209M
Investment Income Net -
Net Interest Income $21M
Interest Income $21M
Interest Expense -
Non Interest Income -
Other Non Operating Income -
Depreciation -
Depreciation And Amortization $964K
Income Before Tax -$208M
Income Tax Expense $51K
Interest And Debt Expense -
Net Income From Continuing Operations -$208M
Comprehensive Income Net Of Tax -
Ebit -$129M
Ebitda -$208M
Net Income -$208M

Revenue & Profitability

Earnings Performance

SYRE Financials

yearly Balance Sheet (As of Dec 31, 2024)

Field Value (USD)
Total Assets $608M
Total Current Assets $608M
Cash And Cash Equivalents At Carrying Value $89M
Cash And Short Term Investments $89M
Inventory -
Current Net Receivables -
Total Non Current Assets $10K
Property Plant Equipment -
Accumulated Depreciation Amortization Ppe -
Intangible Assets -
Intangible Assets Excluding Goodwill -
Goodwill -
Investments -
Long Term Investments -
Short Term Investments $514M
Other Current Assets $5.4M
Other Non Current Assets -
Total Liabilities $91M
Total Current Liabilities $54M
Current Accounts Payable $666K
Deferred Revenue -
Current Debt -
Short Term Debt -
Total Non Current Liabilities $37M
Capital Lease Obligations -
Long Term Debt -
Current Long Term Debt -
Long Term Debt Noncurrent -
Short Long Term Debt Total $85M
Other Current Liabilities $53M
Other Non Current Liabilities $37M
Total Shareholder Equity $518M
Treasury Stock -
Retained Earnings -$972M
Common Stock $13K
Common Stock Shares Outstanding $47M

yearly Cash Flow (As of Dec 31, 2024)

Field Value (USD)
Operating Cashflow -$157M
Payments For Operating Activities -
Proceeds From Operating Activities -
Change In Operating Liabilities -
Change In Operating Assets -
Depreciation Depletion And Amortization $744K
Capital Expenditures $0
Change In Receivables -
Change In Inventory -
Profit Loss -
Cashflow From Investment -$353M
Cashflow From Financing $411M
Proceeds From Repayments Of Short Term Debt -
Payments For Repurchase Of Common Stock -
Payments For Repurchase Of Equity -
Payments For Repurchase Of Preferred Stock -
Dividend Payout -
Dividend Payout Common Stock -
Dividend Payout Preferred Stock -
Proceeds From Issuance Of Common Stock -
Proceeds From Issuance Of Long Term Debt And Capital Securities Net -
Proceeds From Issuance Of Preferred Stock -
Proceeds From Repurchase Of Equity -
Proceeds From Sale Of Treasury Stock -
Change In Cash And Cash Equivalents -
Change In Exchange Rate -
Net Income -$208M

yearly Income Statement (As of Dec 31, 2024)

Field Value (USD)
Gross Profit $886K
Total Revenue $886K
Cost Of Revenue $964K
Costof Goods And Services Sold $964K
Operating Income -$209M
Selling General And Administrative $46M
Research And Development $163M
Operating Expenses $209M
Investment Income Net -
Net Interest Income $21M
Interest Income $21M
Interest Expense -
Non Interest Income -
Other Non Operating Income -
Depreciation -
Depreciation And Amortization $964K
Income Before Tax -$208M
Income Tax Expense $51K
Interest And Debt Expense -
Net Income From Continuing Operations -$208M
Comprehensive Income Net Of Tax -
Ebit -$129M
Ebitda -$208M
Net Income -$208M

SYRE News

SYRE Profile

Spyre Therapeutics Inc. Profile

Sector: HEALTHCARE

Industry: BIOTECHNOLOGY

Spyre Therapeutics, Inc., a biotechnology company, focuses on advancing a pipeline of antibody therapeutics for the treatment of inflammatory bowel disease by combining antibody engineering, rational therapeutic combinations, and precision medicine approaches for patient selection. The company is headquartered in Waltham, Massachusetts.

NXTT
+2.65%
$0.14
NVDA
-2.70%
$167.02
HOUR
+93.12%
$3.65
CGBS
-39.47%
$0.03
PRSO
+68.70%
$1.38
KVUE
-9.34%
$18.62
GNPX
+47.39%
$0.22
ISPC
+27.42%
$0.85
TSLA
+3.63%
$350.84
SNAP
+3.10%
$7.31
SOUN
+7.29%
$14.26
YAAS
-63.98%
$0.10
AAL
+1.71%
$13.08
RIVN
+3.72%
$14.21
PLTR
-1.94%
$153.11
VEEE
+46.39%
$2.84
AVGO
+9.40%
$334.89
AMD
-6.58%
$151.13
GELS
+62.50%
$1.56
SOFI
+0.86%
$25.60
TPIC
-45.91%
$0.12
AXDX
-61.36%
$0.03
WBD
+2.88%
$12.11
HOOD
-1.61%
$101.25
MARA
+0.52%
$15.19
NIO
-2.93%
$5.95
INTC
-0.48%
$24.49
AAPL
-0.03%
$239.69
LYT
-16.77%
$0.09
IXHL
-9.48%
$0.52
BBD
+3.58%
$3.18
ETHD
-2.46%
$3.56
DNN
+3.07%
$2.35
F
+0.51%
$11.74
GOOGL
+1.16%
$235.00
BMNR
-0.35%
$42.04
TLRY
+3.47%
$1.19
BTG
+3.21%
$4.17
BAC
-1.12%
$49.77
RMBL
+60.50%
$3.21
ADD
-25.47%
$0.05
ABEV
+1.82%
$2.23
NOK
-1.08%
$4.55
RIOT
+0.98%
$13.29
LULU
-18.57%
$167.80
AMZN
-1.42%
$232.33
AEO
+0.10%
$18.80
ADAP
-19.60%
$0.04
GRAB
+2.17%
$5.16
HBAN
-1.39%
$17.63
SRM
+53.27%
$10.30
ONDS
+5.62%
$5.63
PFE
+1.38%
$24.88
RGTI
-0.13%
$15.10
LDI
+26.75%
$2.89
LCID
+13.92%
$18.41
QBTS
+0.52%
$15.37
PLUG
+1.38%
$1.46
KEY
-1.25%
$18.94
EQX
+9.03%
$9.77
MSFT
-2.55%
$495.00
JBLU
-0.19%
$5.08
SBET
-3.20%
$14.93
CUTR
-10.19%
$0.09
PET
-59.91%
$0.04
WLGS
-5.57%
$0.04
MU
+5.76%
$131.37
AGNC
+1.66%
$10.37
CIFR
+1.62%
$7.52
RR
-0.39%
$2.52
WULF
+2.93%
$9.13
JOBY
+2.74%
$13.46
ETWO
0.00%
$3.30
BTE
-3.53%
$2.18
GOOG
+1.07%
$235.17
VALE
+1.36%
$10.40
MRVL
-1.20%
$63.33
T
+0.03%
$29.59
DUO
+32.81%
$3.44
HPE
+1.55%
$23.52
PBR
-1.37%
$12.21
CAN
+3.26%
$0.70
HIMS
+0.62%
$48.41
KO
-0.42%
$67.95
BURU
-5.54%
$0.14
IREN
+0.07%
$26.15
AFMD
-34.94%
$0.18
INFY
-1.26%
$16.38
CLF
+8.27%
$11.39
HL
+1.92%
$9.02
ITUB
+1.57%
$7.10
OPAD
+4.71%
$5.11
CMG
-0.84%
$41.06
NUVB
+14.03%
$3.90
SMCI
-0.71%
$40.40
KDP
-2.05%
$28.65
CSCO
-1.60%
$66.90
FIG
+0.54%
$54.86
WFC
-3.50%
$78.95
NVFY
+64.79%
$4.40
NXTT
+2.65%
$0.14
NVDA
-2.70%
$167.02
HOUR
+93.12%
$3.65
CGBS
-39.47%
$0.03
PRSO
+68.70%
$1.38
KVUE
-9.34%
$18.62
GNPX
+47.39%
$0.22
ISPC
+27.42%
$0.85
TSLA
+3.63%
$350.84
SNAP
+3.10%
$7.31
SOUN
+7.29%
$14.26
YAAS
-63.98%
$0.10
AAL
+1.71%
$13.08
RIVN
+3.72%
$14.21
PLTR
-1.94%
$153.11
VEEE
+46.39%
$2.84
AVGO
+9.40%
$334.89
AMD
-6.58%
$151.13
GELS
+62.50%
$1.56
SOFI
+0.86%
$25.60
TPIC
-45.91%
$0.12
AXDX
-61.36%
$0.03
WBD
+2.88%
$12.11
HOOD
-1.61%
$101.25
MARA
+0.52%
$15.19
NIO
-2.93%
$5.95
INTC
-0.48%
$24.49
AAPL
-0.03%
$239.69
LYT
-16.77%
$0.09
IXHL
-9.48%
$0.52
BBD
+3.58%
$3.18
ETHD
-2.46%
$3.56
DNN
+3.07%
$2.35
F
+0.51%
$11.74
GOOGL
+1.16%
$235.00
BMNR
-0.35%
$42.04
TLRY
+3.47%
$1.19
BTG
+3.21%
$4.17
BAC
-1.12%
$49.77
RMBL
+60.50%
$3.21
ADD
-25.47%
$0.05
ABEV
+1.82%
$2.23
NOK
-1.08%
$4.55
RIOT
+0.98%
$13.29
LULU
-18.57%
$167.80
AMZN
-1.42%
$232.33
AEO
+0.10%
$18.80
ADAP
-19.60%
$0.04
GRAB
+2.17%
$5.16
HBAN
-1.39%
$17.63
SRM
+53.27%
$10.30
ONDS
+5.62%
$5.63
PFE
+1.38%
$24.88
RGTI
-0.13%
$15.10
LDI
+26.75%
$2.89
LCID
+13.92%
$18.41
QBTS
+0.52%
$15.37
PLUG
+1.38%
$1.46
KEY
-1.25%
$18.94
EQX
+9.03%
$9.77
MSFT
-2.55%
$495.00
JBLU
-0.19%
$5.08
SBET
-3.20%
$14.93
CUTR
-10.19%
$0.09
PET
-59.91%
$0.04
WLGS
-5.57%
$0.04
MU
+5.76%
$131.37
AGNC
+1.66%
$10.37
CIFR
+1.62%
$7.52
RR
-0.39%
$2.52
WULF
+2.93%
$9.13
JOBY
+2.74%
$13.46
ETWO
0.00%
$3.30
BTE
-3.53%
$2.18
GOOG
+1.07%
$235.17
VALE
+1.36%
$10.40
MRVL
-1.20%
$63.33
T
+0.03%
$29.59
DUO
+32.81%
$3.44
HPE
+1.55%
$23.52
PBR
-1.37%
$12.21
CAN
+3.26%
$0.70
HIMS
+0.62%
$48.41
KO
-0.42%
$67.95
BURU
-5.54%
$0.14
IREN
+0.07%
$26.15
AFMD
-34.94%
$0.18
INFY
-1.26%
$16.38
CLF
+8.27%
$11.39
HL
+1.92%
$9.02
ITUB
+1.57%
$7.10
OPAD
+4.71%
$5.11
CMG
-0.84%
$41.06
NUVB
+14.03%
$3.90
SMCI
-0.71%
$40.40
KDP
-2.05%
$28.65
CSCO
-1.60%
$66.90
FIG
+0.54%
$54.86
WFC
-3.50%
$78.95
NVFY
+64.79%
$4.40

Charts powered by TradingView


Market data may be delayed by 15 minutes or more and is provided by financial exchanges or third-party providers. AfterPullback does not verify or guarantee its accuracy and assumes no responsibility to do so. This website is not operated by a licensed attorney, accountant, or financial advisor. Nothing on this site constitutes financial advice or replaces consultation with a qualified professional who understands your specific circumstances. Always consult a licensed financial advisor before making investment decisions.